




[図1A]




[図1B]




[図2]




[図3]




[図4]



[図5]




[図6]





[図7]

PKR阻害因子の融合配列を用いたSeV再構成




[図8]

LLC-MK2-F CAG EFnpL EFnCAGpL CAGnpEFL




[図9]




[図10]

PKR阻害因子の組み合わせを用いたSeV再構成




[図11]

PKR阻害因子の組み合わせを用いた
SeV再構成の感染力価測定




[図12]

PKR阻害因子をSeVの搭載遺伝子に付加した
SeV再構成




[図13]


PKR阻害因子をSeVの搭載遺伝子に付加した
SeV再構成の感染力価測定




[図14]




[図15]




[図16]




[図17]




[図18]




[図19]




[図20]



[図21A]




[図21B]




[図22]

PKR阻害因子を用いたMuVの再構成




[図23]

PKR阻害因子を用いたMeVの再構成




[図24]

PKR阻害因子を用いたVSVの再構成




[図25]

異種RNAポリメラーゼを用いたSeV、MeV、MuVの再構成




[図26]

異種RNAポリメラーゼを用いたVSVの再構成



[図27A]



[図27B]

